Status | Study |
Recruiting |
Study Name: A Study Evaluating Venetoclax in Subjects With Chronic Lymphocytic Leukemia Whose Cancer Has Come Back or Who Had No Response to Previous Cancer Treatments Including Subjects Missing Part of Their Chromosome 17, or TP53 Gene Mutation; or Who Received Prior Treatment With a B-Cell Receptor Inhibitor Condition: Chronic Lymphocytic Leukemia (CLL) Date: 2016-11-30 Interventions: Drug: Venetoclax Tablet Other Name: ABT-199 |
Not yet recruiting |
Study Name: A Study Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion Condition: Chronic Lymphocytic Leukemia (CLL) Date: 2016-11-15 Interventions: Drug: Venetoclax tablet Other Names: |
Recruiting |
Study Name: A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor. Condition: Chronic Lymphocytic Leukemia Date: 2016-04-26 Interventions: Drug: Venetoclax Tablets Other Name: ABT-199 |
Recruiting |
Study Name: Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Condition: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Date: 2014-11-19 Interventions: Drug: acalabrutinib Patients u |
Terminated |
Study Name: Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion Condition: B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion Date: 2014-01-22 Interventions: Drug: Idelalisib 150 mg tablet |
Completed |
Study Name: Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia Condition: Chronic Lymphocytic Leukemia Date: 2013-12-03 Interventions: Drug: Ruxolitinib 20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progres |
Active, not recruiting |
Study Name: A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion Condition: Chronic Lymphocytic Leukemia 17 p Deletion Date: 2013-06-26 Interventions: Drug: ABT-199 Tablet |
Completed |
Study Name: A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion Condition: Chronic Lymphocytic Leukemia With 17p Deletion Small Lymphocyti Date: 2012-12-03 Interventions: Drug: Ibrutinib All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily. |
Completed |
Study Name: Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) Condition: Multiple Myeloma Date: 2012-10-29 Interventions: Drug: POMALIDOMIDE hard capsul |
Active, not recruiting |
Study Name: PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Condition: Leukemia Leukemia, Lymphocytyc CLL (Chronic Lymphocytic Le Date: 2011-12-22 Interventions: Drug: PCI 32765 420 mg daily |